Oncology
Refine search
Pharmaceutical
Servier, an independent pharma governed by a foundation, has published its financial results for the 2024/25 financial year. 27 January 2026
Biotechnology
Hangzhou, China-based privately-held HealZen Therapeutics has announced a new strategic partnership with an unnamed US biotech company to advance degrader–antibody conjugate (DAC) therapeutics, marking the first cross-border collaboration for this modality. 27 January 2026
Biotechnology
US drugmakers Moderna and Merck & Co last week released new data on the former’s intismeran autogene and Merck’s Keytruda in the treatment of melanoma. UK pharma major GSK announced an agreement to acquire RAPT Therapeutics, along with its ozureprubart for $2.2 billion. Johnson & Johnson was the first big pharma to announce fourth quarter 2025 financials and forecast further growth. Also of note, Janux Therapeutics entered a collaboration with Bristol Myers Squibb for its investigational oncology drug JANX007 that could earn the company $850 million. 25 January 2026
Pharmaceutical
Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today, the UK health technology assessor, National Institute for Health and Care Excellence announced today. 23 January 2026
Pharmaceutical
USA-based Medicus Pharma’ Antev subsidiary has agreed to amend its licensing deal with UK-based medical research organization LifeArc relating to teverelix, an investigational next generation long-acting GnRH antagonist. 23 January 2026
Biotechnology
Japanese pharma Daiichi Sankyo and British partner AstraZeneca said Enhertu (trastuzumab deruxtecan) has been approved in China as a second-line treatment for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma after one trastuzumab-based regimen. 23 January 2026
Biotechnology
Privately-held UK drug developer Ellipses Pharma has entered into a collaboration and licence agreement with China-based Innolake Biopharm to develop a clinical stage first-in-class antibody drug conjugate (ADC). 23 January 2026
Pharmaceutical
US biopharma Corcept Therapeutics says its Phase III ROSELLA trial met its overall survival primary endpoint for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, adding fresh momentum to the company’s regulatory push. 23 January 2026
Biotechnology
Janux Therapeutics’ shares closed up 14% at $15.14, after it announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. 23 January 2026
Biosimilars
India’s Zydus Lifesciences, an innovation-led life-sciences company with an international presence, has launched the world’s first biosimilar of nivolumab in India under the brand name Tishtha, reinforcing the company’s growing capability in advanced biologics and immuno-oncology. 22 January 2026
Pharmaceutical
US healthcare giant Johnson & Johnson has announced results for fourth-quarter and full-year 2025. 21 January 2026
Biotechnology
South Korean CDMO Samsung Biologics said fourth-quarter 2025 revenue rose 35% year-on-year to 1,286 billion won ($877 million), with operating profit up 68% to 528 billion won, with the firm's key Plants 1–3 and Plant 4 running at full utilization. 21 January 2026
Biotechnology
German biotech BioNTech today announced that the US Food and Drug Administration (FDA) has granted fast track designation to BNT113, an investigational mRNA cancer immunotherapy. 21 January 2026
Biotechnology
France-based ErVimmune, a biotech developing therapeutic vaccines targeting new families of unconventional tumor antigens derived from human endogenous retroviruses (HERVs), has announced the first closing of its Series A financing. 21 January 2026
Biotechnology
San Diego, USA-based ViroMissile has announced the appointment of Michael Wood as chief business officer (CBO). In this role, Mr Wood will lead ViroMissile’s corporate strategy, fundraising, and partnering activities as the company advances its proprietary IDOV platform toward key clinical and strategic milestones. 21 January 2026
Biotechnology
UK-based Infinitopes, a cancer vaccine biotech company, has announced the successful completion of the second close of its seed financing round, securing an additional $15.4 million and bringing the total raised to $35.1 million. 21 January 2026
Pharmaceutical
The US Food and Drug Administration (FDA) yesterday issued a draft guidance for industry that provides recommendations to sponsors about using minimal residual disease (MRD) and complete response (CR) as primary endpoints in trials evaluating drugs and biologics intended to treat patients with multiple myeloma to support approval under the accelerated approval regulations. 21 January 2026
Biotechnology
Calfornian immunotherapy company ImmunityBio has announced that it has held a Type B End-of-Phase meeting with the US Food and Drug Administration (FDA) regarding the company’s supplemental Biologics License Application (sBLA) for Anktiva (nogapendekin alfa inbakicept) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors. 20 January 2026
Biotechnology
USA-based mRNA vaccines company Moderna’s shares were flat in pre-market activity, as the company announced awaited new clinical data on its investigational mRNA-based individualized neoantigen therapy (INT). 20 January 2026
Biotechnology
South Korean biotech Alteogen has signed an exclusive license agreement with Tesaro, a unit of GSK, granting Tesaro worldwide rights to use Alteogen’s ALT-B4 enzyme to develop a subcutaneous formulation of Jemperli (dostarlimab). 20 January 2026
Biotechnology
Oxford, UK-based Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX 011, a first in class, mutation agnostic antibody with potential to disrupt the $2 billion essential thrombocythemia (ET) market. 16 April 2026
Biotechnology
US biotech Terremoto Biosciences, a firm developing highly-targeted small molecule medicines, has announced the closing of a $108 million Series C financing round. 16 April 2026
Biotechnology
UK-based STORM Therapeutics, a biotech targeting RNA modifications to reprogram cells and develop novel cancer therapies, has announced a successful $56 million Series C financing. 16 April 2026
Pharmaceutical
US-based Sonire Therapeutics has secured $18 million in Series A financing to advance clinical development of its non-invasive cancer therapy, with a focus on pancreatic cancer. The round was led by Santé Ventures, with participation from Fast Track Initiative, Nomura SPARX Investment and SBI Investment. 16 April 2026
Pharmaceutical
In what looks to be the largest follow-on stock offering in biopharma history, US oncology company Revolution Medicines priced 10.56 million shares to raise $1.5 billion and $500 million in convertible senior notes due 2033. 16 April 2026
Biotechnology
Privately-held Swiss drug firm Ewopharma has reported that sugemalimab, licensed from Chinese partner CStone Pharmaceuticals, has received I, A recommendation in the European Society for Medical Oncology (ESMO) Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline. 16 April 2026
Pharmaceutical
Johnson & Johnson has announced its financial results for the first quarter of 2026. 15 April 2026
Biotechnology
USA-based Galera Therapeutics and Obsidian Therapeutics, a privately-held clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocyte (TIL) cell therapies, announced that they have entered into a definitive merger agreement to combine in an all-stock transaction. 15 April 2026
Biotechnology
San Diego, USA-based biotech Neomorph has announced the closing of a $100 million Series B financing. The round was led by Deerfield Management with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute, and others. 15 April 2026
Biotechnology
Texan pre-clinical stage biotech CrossBridge Bio, a developer of dual-payload antibody-drug conjugates (ADCs), has announced a definitive agreement to be acquired by US pharma major Eli Lilly. 14 April 2026
Biotechnology
Eli Lilly has announced positive top-line results from the Phase III BRUIN CLL-322 trial. 14 April 2026
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $75 million Series C financing round. 14 April 2026
Biotechnology
Anglo-Irish biopharma SynOx Therapeutics announced that the US Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to emactuzumab for the treatment of tenosynovial giant cell tumors (TGCT) patients that are not amenable to or who would not benefit from surgery. 14 April 2026
Biotechnology
Dutch biotech Laigo Bio, which is pioneering novel and highly differentiated therapies using its proprietary SureTACs precision membrane protein degradation platform, has appointed Dr Richard Sainson as its new chief scientific officer (CSO). 14 April 2026
Biotechnology
US biotech major Regeneron Pharmaceuticals and Australian radiopharmaceuticals specialist Telix Pharmaceuticals have announced a collaboration, sending the latter company’s shares up by 8% in Monday’s trading. 13 April 2026
Pharmaceutical
Revolution Medicines today announced positive top-line results from its global, randomized, controlled Phase III RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had been previously treated. 13 April 2026
Generics
The Russian Ministry of Health has begun more active cancelling of tenders for drug procurements, waiting for the launch of cheaper generics, as the federal budget experiences a shortage of funds for procurements of expensive original drugs. 13 April 2026
Biotechnology
UK pharma major GSK has announced positive findings from its global Phase I BEHOLD-1 clinical trial for mocertatug rezetecan (or Mo-Rez for short), a novel antibody-drug conjugate (ADC) targeting the B7-H4 antigen. 13 April 2026
Biotechnology
Chinese clinical-stage biotech OriCell Therapeutics announced the cumulative closing of a pre-initial public offering (IPO) financing round in excess of $110 million. 13 April 2026
Biotechnology
US biotech Replimune has suffered a fresh blow after the US Food and Drug Administration rejected its lead cancer therapy RP1 (vusolimogene oderparepvec), sending shares sharply lower and casting doubt over the program’s future. 13 April 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze